The DESTINY-Breast06 trial investigated earlier and broader use of trastuzumab deruxtecan in patients with metastatic hormone-receptor-positive breast cancer, and demonstrated improvements in progression-free survival over standard chemotherapy. These data provide a meaningful advance; however, this strategy might not be right for all patients, and careful consideration is recommended before blanket use.

中文翻译：

---

扩大 T-DXd 在转移性 HR 阳性乳腺癌中的应用：我们现在在哪里？


DESTINY-Breast06 试验研究了曲妥珠单抗 deruxtecan 在转移性激素受体阳性乳腺癌患者中的早期和更广泛应用，并证明与标准化疗相比，无进展生存期有所改善。这些数据提供了有意义的进步;然而，这种策略可能并不适合所有患者，建议在使用毯子之前仔细考虑。